611 W. Union Street
Benson, AZ 85602
(520) 586-0800

member support line
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line


611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line


powered by centersite dot net
Health Sciences
Basic InformationLatest News
Scientists Create Embryos With Cells From Monkeys, Humans'Game of Thrones' Study Reveals the Power of Fiction on the MindScientists Create Human Tear Glands That Cry in the LabAHA News: How Grief Rewires the Brain and Can Affect Health – and What to Do About ItCould Taking a Swing at Golf Help Parkinson's Patients?Autopsy Study May Explain Why Some COVID Survivors Have 'Brain Fog'Gene Study Probes Origins of Addison's DiseaseCould a Common Prostate Drug Help Prevent Parkinson's?AHA News: Hormones Are Key in Brain Health Differences Between Men and WomenNerve Drug Might Curb Spinal Cord Damage, Mouse Study SuggestsIs There a 'Risk-Taking' Center in the Brain?AHA News: Dr. Dre Recovering From a Brain Aneurysm. What Is That?Can 2 Nutrients Lower Your Risk for Parkinson's?New Clues to How Cancers Originate in the BrainBrain May Age Faster After Spinal Cord InjuryScans Reveal How COVID-19 Can Harm the BrainWhat Loneliness Looks Like in the BrainNeurologists Much Tougher to Find in Rural AmericaCOVID-19 Survival Declines When Brain Affected: StudyAs Testing Costs Rise, Neurology Patients May Skip ScreeningGene Therapy Shows No Long-Term Harm in Animals: StudyCould Gene Therapy Cure Sickle Cell Disease? Two New Studies Raise HopesCocoa Might Give Your Brain a Boost: StudyLockdown Loneliness Could Worsen Parkinson's SymptomsChildhood Lead Exposure Tied to Brain Changes in Middle AgeStaying Social Can Boost Healthy 'Gray Matter' in Aging BrainsDNA Analysis Might Reveal Melanoma RiskGenetics Might Explain Some Cases of Cerebral PalsyDiabetes Drug Metformin May Protect the Aging BrainNew Research Links Another Gene to Alzheimer's RiskYour Sex Affects Your Genes for Body Fat, Cancer, Birth WeightExperimental Drug Shows Promise Against ALSCould Gene Therapy Stem the Damage of Parkinson's?Genetic Research May Help Identify Causes of StillbirthBlood Test Heralds New Era in Alzheimer's DiagnosisMore Clues to the Genes Behind Hearing LossScientists Move Closer to Mapping Entire Human GenomeBlood Test May Reveal Concussion Severity With Accuracy of Spinal TapDeep Brain Stimulation May Slow Parkinson's, Study FindsStroke, Confusion: COVID-19 Often Impacts the Brain, Study ShowsYour Genes May Affect How You'll Heal If WoundedEven Without Concussion, Athletes' Brains Can Change After Head Jolts: StudyHealthDay In-Depth
The AI Revolution: For Patients, Promise and Challenges Ahead">HealthDay In-Depth
The AI Revolution: For Patients, Promise and Challenges Ahead
Blood Test Might Predict Worsening MSKeto Diet Might Change Your Gut in More Ways Than OneParkinson's Patient Improving After First-Ever Stem Cell TherapyKey Areas of the Brain Triggered in Recent Heart Attack SurvivorsFirst Good Evidence That Brain Hits 'Replay' While You SleepSome NFL Players May Be Misdiagnosed With Brain Disease: StudyGreenhouse Gases Bad for Your Brain
Questions and AnswersLinksBook Reviews
Related Topics

Medical Disorders
Mental Disorders
Mental Health Professions

Blood Test Might Predict Worsening MS

HealthDay News
by By Serena Gordon
HealthDay Reporter
Updated: May 21st 2020

new article illustration

THURSDAY, May 21, 2020 (HealthDay News) -- A new blood test might help doctors predict whether someone's multiple sclerosis may soon get worse.

The test looks for a substance called neurofilament light chain. It's a nerve protein that can be detected when nerve cells die. People with higher levels of it were more likely to have worsening MS effects within the next year.

"In a disease like MS that is so unpredictable and varies so much from one person to the next, having a noninvasive blood test like this could be very valuable, especially since treatments are most effective in the earliest stages of the disease," lead investigator Ali Manouchehrinia said in a news release from the journal Neurology, where the study was published online May 20.

Manouchehrinia is an assistant professor of clinical neuroscience at the Karolinska Institute in Stockholm, Sweden.

His study of the neurofilament light chain blood test included almost 4,400 people with multiple sclerosis and a control group of more than 1,000 people without it.

In MS, the body's immune system attacks the central nervous system, commonly leading to problems with balance and walking that come and go.

Over five years, volunteers provided blood samples and their health was followed to see whose disability worsened. Researchers also checked for signs of a more serious form of MS called secondary progressive MS, in which disability gets worse little by little and then becomes more constant.

The study controlled the data to account for factors that might lead to worsening disability, such as length of time with MS.

People with MS had far more neurofilament light chain in their blood than did people without the disease, the study found.

And those with high levels of the nerve protein were 40% to 70% more likely to see their disability get worse within the next year compared to those with low levels.

Higher protein levels also translated to a 50% greater chance for a moderate disability that affected everyday life, but not people's ability to walk.

People with higher protein levels were also 50% more likely to develop a disability that impaired walking, but could still walk about one-third of a mile without help or taking a break.

Overall, 16% (525 people) had a moderate level of disability during the five-year study. Nine percent (352 people) developed significant disability.

While the test could predict a much higher risk of disability, it couldn't definitively show whether or not someone would have a disability.

Manouchehrinia said that it's possible that other medical conditions not studied may affect neurofilament light chain levels. More study is needed.

Dr. Asaff Harel, a neurologist at Lenox Hill Hospital in New York City, said the blood test may have a place with current MS monitoring such as MRI and physical exams.

"These results add to the growing body of literature looking at blood neurofilament light chain levels as a tool to predict long-term prognosis in MS," Harel said.

Mark Allegretta, vice president of research for the National Multiple Sclerosis Society, noted that the study was a large one, with more than 1,000 controls.

"This study adds a lot of confidence that neurofilament light chain levels will be useful in MS," he said.

Like Harel, Allegretta also predicted that the blood screening would one day be used in combination with other tests.

"With many of these tools, the information is additive. We're not looking to rely on any single test," he said.

Right now, MRI is used to track the course of the disease. But Allegretta said a blood test has advantages: It's more standardized than an imaging test and could be done more often and for a lower cost.

Allegretta said the test could be useful in clinical studies to see whether someone is responding to a treatment. It is at least a few years away, he added.

More information

Learn more about MS from the National Multiple Sclerosis Society.